Binds to a molecule on the surface of T cells. Used to prevent acute rejection of organ, e.g., kidney, transplants. Binds to CD22, a molecule found on some B-cell leukemias . Binds to part of the IL-2 receptor produced at the surface of activated T cells. Used to prevent acute rejection of transplanted kidneys.
Shows promise against some inflammatory diseases such as rheumatoid arthritis .
The only monoclonal so far that seems to be effective against solid tumors. CMA-676 is the first immunotoxin that shows promise in the fight against cancer. In Phase II clinical trials , Vitaxin has shown some promise in shrinking solid tumors without harmful side effects. Inhibits the clumping of platelets by binding the receptors on their surface that normally are linked by fibrinogen. Helpful in preventing reclogging of the coronary arteries in patients who have undergone angioplasty.